Department of Physical Education, University of Brasília, Brasília, Brazil.
Interdisciplinary Research Department, University Center ICESP, Brasília, Brazil.
Nutr Clin Pract. 2022 Dec;37(6):1356-1365. doi: 10.1002/ncp.10819. Epub 2022 Jan 7.
The SARC-F questionnaire assesses sarcopenia risk. The addition of a calf circumference measurement, known as SARC-CalF, has been recently proposed. We investigated possible associations of SARC-F and SARC-CalF with sarcopenia traits in patients undergoing hemodialysis.
Thirty patients (17 men; 57 ± 15 years) were enrolled. Sarcopenia risk was assessed by SARC-F (≥4) and SARC-CalF (≥11). Probable (low muscle strength or low skeletal muscle mass [SMM]) and confirmed (both) sarcopenia were diagnosed as recommended by the revised European Working Group on Sarcopenia in Older People. Muscle strength was assessed by handgrip strength (HGS) and five-time sit-to-stand test (STS-5), and physical performance was evaluated by gait speed. SMM was assessed by bioelectrical impedance.
Sarcopenia risk by the SARC-F and SARC-CalF were found in 23% (n = 7) and 40% (n = 12) patients, respectively. The SARC-F and SARC-CalF were both associated with physical function, but not with SMM. Probable sarcopenia by HGS was associated with SARC-F and SARC-CalF. Moreover, both showed moderate Kappa agreement with slowness and probable sarcopenia by HGS and/or STS-5, but only SARC-CalF with probable sarcopenia by HGS. A larger sensitivity was found for SARC-CalF than SARC-F in detecting probable sarcopenia by HGS (70% vs 30%) and by HGS and/or STS-5 (63% vs 44%).
SARC-F and SARC-CalF are associated with sarcopenia traits in patients undergoing hemodialysis. SARC-CalF seems to be more strongly associated with sarcopenia traits and present a higher sensitivity for probable sarcopenia than SARC-F, as it adds a direct measurement.
SARC-F 问卷评估肌少症风险。最近提出了一种添加小腿围测量的方法，称为 SARC-CalF。我们研究了 SARC-F 和 SARC-CalF 与接受血液透析的患者肌少症特征之间的可能关联。
共纳入 30 名患者（男 17 名；57 ± 15 岁）。通过 SARC-F（≥4）和 SARC-CalF（≥11）评估肌少症风险。按照修订后的欧洲老年人肌少症工作组的建议，诊断可能（低肌肉力量或低骨骼肌量 [SMM]）和确诊（两者均）肌少症。肌肉力量通过握力（HGS）和五次坐站测试（STS-5）评估，身体机能通过步态速度评估。SMM 通过生物电阻抗评估。
SARC-F 和 SARC-CalF 预测的肌少症风险分别见于 23%（n = 7）和 40%（n = 12）的患者。SARC-F 和 SARC-CalF 均与身体机能相关，但与 SMM 无关。HGS 提示的可能肌少症与 SARC-F 和 SARC-CalF 相关。此外，SARC-F 和 SARC-CalF 与 HGS 和/或 STS-5 提示的行动缓慢和可能的肌少症均具有中等程度的 Kappa 一致性，但仅 SARC-CalF 与 HGS 提示的可能肌少症具有一致性。SARC-CalF 检测 HGS 提示的可能肌少症（70%比 30%）和 HGS 和/或 STS-5 提示的可能肌少症（63%比 44%）的灵敏度更高。
SARC-F 和 SARC-CalF 与接受血液透析的患者的肌少症特征相关。SARC-CalF 似乎与肌少症特征的相关性更强，并且比 SARC-F 检测可能的肌少症的灵敏度更高，因为它增加了直接测量。
